Preview

Russian Neurosurgical Journal named after Professor A. L. Polenov

Advanced search

Neuroblastoma and ganglioneuroblastoma of the central nervous system in adult patients: clinical and molecular genetic aspects

https://doi.org/10.56618/2071-2693_2023_15_3_77

Abstract

SUMMARY. Neuroblastoma (NB) and ganglioneuroblastoma (GNB) of the central nervous system are rare (1 % of all tumors) and poorly studied malignant embryonic tumors in adult patients. Now, the molecular genetic features of tumors and the prognosis of the disease for adult patients have not been sufficiently studied, and there are no generally accepted standards of therapy.

PURPOSE OF THE STUDY. To identify factors that affect progression-free survival (PFS) and overall survival (OS) of adult patients with NB and GNB based on the study of their clinical and morphological characteristics, treatment parameters, and molecular genetic profile.

MATERIALS AND METHODS. A retro-prospective study was conducted, which included 15 patients with NB and 16 patients with GNB aged 18 years and older. The histological diagnosis was established after immunohistochemical examination of the tumor material (staining for Syn, NSE, GFAP, CD 99, Ki67). Real-Time PCR was used to evaluate mRNA expression of TP, MGMT, ERCC 1, PDGFR-α, VEGF, C-kit, and β-tubulin III genes. Patients were studied clinical and molecular genetic characteristics, treatment approaches and long-term results.

RESULTS. Patients with GNB had both a higher risk of recurrence (HR = 2.67; 95 % CI 1.10–6.47; p = 0.022) and a higher risk of death (HR = 8.88; 95 % CI 1.99–39.50; p = 0.00045), compared with patients with NB. Given the difference in survival between NB and GNB, further statistical analysis was performed separately for each group of patients. Thus, in patients with NB, tumor removal of 50 % or more increased OS compared to biopsy by 37.0 months (p = 0.042). While in patients with GNB, total tumor resection increased both PFS by 10.8 months and OS by 28.3 months, even compared with subtotal resection (p = 0.014 and p = 0.017, respectively). In the group of patients with GNB, chemotherapy (ChT) in the amount of 6 cycles with temozolomide increased the FFS and OS compared with other chemotherapy regimens (p=0.026 and p=0.025, respectively). According to the results of molecular genetic profiling of tumors, the absence of a high level of expression of the VEGF gene in NB attracted attention. In GNB, a high level of expression was found in the PDGFR-α (53.8 %, 7/13), VEGF (53.8 %, 7/13) and β-tubulin III (84.6 %, 11/13) genes. Expression of VEGF above the average level (ΔCt < –1.0) significantly increased the risk of recurrence and death both in the general group of patients and in the GNB group.

CONCLUSION. The morphological type of the tumor significantly influenced the duration of PFS and OS in adult patients. The radical nature of surgical treatment affected survival in both groups, but especially in the group of patients with GNB. In patients with GNB, chemotherapy in the amount of 6 cycles with temozolomide increased the PFS and OS. The key molecular genetic prognostic marker in adult patients with GNB is the VEGF gene.

About the Authors

A. S. Nechaeva
Polenov Neurosurgical Research Institute — Branch of the Almazov National Medical Research Centre; World-Class Research Centre for Personalized Medicine
Russian Federation

Anastasia Sergeevna Nechaeva 

Mayakovskogo st., 12, St. Petersburg, 191014

Akkuratova st., 2, St. Petersburg, 197341



M. V. Matsko
Napalkov State Budgetary Healthcare Institution «Saint-Petersburg clinical scientific and practical center for specialised types of medical care (oncological); St. Petersburg University, Universitetskaya Embankment; Saint-Petersburg Medico-Social Institute
Russian Federation

Marina Vitalievna Matsko 

Leningradskaya st., 68a lit. A, St. P etersburg, 197758

7–9, St Petersburg, 199034

Kondratievsky pr., 72, lit. A, St. P etersburg, 195271



A. Yu. Ulitin
Polenov Neurosurgical Research Institute — Branch of the Almazov National Medical Research Centre; North-Western State Medical University named after I. I. Mechnikov
Russian Federation

Alexey Yurievich Ulitin 

Mayakovskogo st., 12, St. Petersburg, 191014

Kirochnaya st., 41, St. Petersburg, 191015



E. N. Imyanitov
N.N. Petrov National Medicine Research Center of oncology; St. Petersburg State Pediatric Medical University
Russian Federation

Evgeny Naumovich Imyanitov 

Leningradskaya st., 68, St. Petersburg, 197758

Litovskaya st., 2, St. Petersburg, 194100



A. G. Iyevleva
N.N. Petrov National Medicine Research Center of oncology
Russian Federation

Aglaya Gennadievna Iyevleva 

Leningradskaya st., 68, St. Petersburg, 197758



I. V. Bizin
N.N. Petrov National Medicine Research Center of oncology
Russian Federation

Ilya Valeryevich Bizin 

Leningradskaya st., 68, St. Petersburg, 197758



References

1. David N. L., Arie P., Pieter W., Daniel J. B., Ian A. C., Dominique F. B., et al. The 2021 W HO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231–51. DOI: 10.1093/neuonc/noab106

2. Louis D. N., Perry A., Reifenberger G., von Deimling A., Figarella-Branger D., Cavenee W. K., et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica. 2016;131(6):803–20. DOI: 10.1007/s00401‑016‑1545‑1

3. Ostrom Q. T., Price M., Neff C. et al. CBTRU S statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2015–2019. Neuro Oncol. 2022;24(Supplement_5): v1–v95. DOI: 10.1093/neuonc/noac202

4. Baehring J., Brem S., Butowski N., et al. Continue NCCN Guidelines Panel Disclosures NCCN Guidelines Version 2.2021 Central Nervous System Cancers [Internet]. 2021. Available from: www.nccn.org/home/

5. Tanaka M., Shibui S., Nomura K., et al. Pineal ganglioneuroblastoma in an adu lt. J N eurooncol. 1999; 44:169–73. DOI: 10.1023/A:1006308205805

6. Nishihara H., Ozaki Y., Ito T., et al. A case of cerebral ganglioneuronal tumor in the parietal lobe of an adult. Brain Tumor Pathol. 2008;25(1):45–9. DOI: 10.1007/s10014‑008‑0229‑5

7. Hosaka T., Nukui H., Koizumi H., et al. Ganglioneuroblastoma of the Anterior Skull Base with a Long-term Follow-up Case Report. Neurol Med Chir (Tokyo). 1982;22(9):757–62. DOI: 10.2176/nmc.22.757

8. Schipper M. H., Van Duinen S. G., Taphoorn M. J., et al. Cerebral ganglioneuroblastoma of adult onset: Two patients and a review of the literature. Clinical Neurology and Neurosurgery. 2012; 114(6):529–34. DOI: 10.1016/j.clineuro.2012.03.015

9. Sturm D., Orr B. A ., Toprak U . H., et al. New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell. 2016 Feb 25;164(5):1060–72. DOI: 10.1016/j.cell.2016.01.015

10. Schwalbe E. C., Hayden J. T., Rogers H. A., et al. Histologically defined central nervous system primitive neuro-ectodermal tumours (CNS-PNETs) display heterogeneous DNA methylation profiles and show relationships to other paediatric brain tumour types. Acta Neuropathol. 2013;126(6):943–6. DOI: 10.1007/s00401‑013‑1206‑6

11. Korshunov A., Okonechnikov K., Schmitt-Hoffner F., et al. Molecular analysis of pediatric CNS-PNET revealed nosologic heterogeneity and potent diagnostic markers for CNS neuroblastoma with FOXR 2-activation. Acta Neuropathol Commun. 2021;9(1):20. DOI: 10.1186/s40478‑021‑01118‑5

12. Hwang E. I., Kool M., Burger P. C., et al. Extensive Molecular and Clinical Heterogeneity in Patients with Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children’s Oncology Group Randomized ACNS 0332 Trial. J Clin Oncol. 2018;36:3388–95. DOI: 10.1200/JCO.2017.

13. Mitiushkina N.V., Iyevleva A. G., Poltoratskiy A. N. et al. Detection of EGFR mutations and EML 4-AL K rearrangements in lung adenocarcinomas using archived cytological slides. Cancer cytopathol. 2013;121(7):370–6. DOI: 10.1002/cncy.21281

14. Wen P. Y., Macdonald D. R., Reardon D. A., et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963–72. DOI: 10.1200/JCO.2009.26.3541

15. Bennett J. J., Rubinstein L. J. The biological behavior of primary cerebral neuroblastoma: A reappraisal of the clincal course in a series of 70 cases. Annals of Neurology. 1984;16(1):21–7. DOI: 10.1002/ana.410160106

16. Lu X., Zhang X., Deng X., et al. Incidence, Treatment, and Survival in Primary Central Nervous System Neuroblastoma. World Neurosurg. 2020;140: e61–72. DOI: 10.1016/j.wneu.2020.04.145

17. Ulitin A. Yu., Matsko M. V., Kobyakov G. L., et al. Practical recommendations for drug treatment of primary tumors of the central nervous system. Malignant Tumors: Practice Guidelines RU SSCO #3s2, 2022 (12). 113–140. doi: 10.18027/2224‑5057‑2022‑12‑3s2‑113‑140 (in Russ.)

18. Nakazato Y., Hosaka N. A 32-year-old man with left temporal lobe tumor. Neuropathology. 2004;24(3):261–2. DOI: 10.1111/j.1440-1789.2004.00556.x

19. Akin M., Ergen Ş. A., Öz B., et al. Ventricular ganglioneuroblastoma in an adult and successful treatment with radiotherapy. Balkan Med J. 2014;31(2):173–6. DOI: 10.5152/balkanmedj.2014.13155

20. Korshunov A., Capper D., Reuss D., et al. Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. Acta Neuropathol. 2016;131(1):137–46. DOI: 10.1007/s00401‑015‑1493‑1


Review

For citations:


Nechaeva A.S., Matsko M.V., Ulitin A.Yu., Imyanitov E.N., Iyevleva A.G., Bizin I.V. Neuroblastoma and ganglioneuroblastoma of the central nervous system in adult patients: clinical and molecular genetic aspects. Russian Neurosurgical Journal named after Professor A. L. Polenov. 2023;15(3):77-87. (In Russ.) https://doi.org/10.56618/2071-2693_2023_15_3_77

Views: 40


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2071-2693 (Print)